Dr Liu on the Ongoing Investigation of Zidesamtinib in ROS1+

Stephen V. Liu, MD, discusses the potential benefits and ongoing investigation of zidesamtinib for patients with ROS1-positive tumors.

Related Keywords

Stephenv Liu , , Georgetown University , Georgetown Lombardi Comprehensive Cancer Center , Thoracic Oncology , Developmental Therapeutics , News , Lung Cancer , Os1 Positive Tumors , Nvl 520 , Zidesamtinib ,